

What is Claimed is:

1. A method of treating a patient for a substance P-related disease, disorder or condition, comprising administering to said patient a therapeutically effective amount of a peptidase that cleaves selectively at Xaa-Pro sequences, wherein said substance P-related disease, disorder or condition is selected from the group consisting of: a CNS disorder; addiction withdrawal; neuropathic pain; postherpetic pain; a neurodegenerative disorder; an autoimmune disease; a disorder of the gastrointestinal tract; a vasospastic disease; a skin disorder or condition; a collagen-related disorder; a cardiovascular disease or condition; an urinary tract disorder; an arthritic disease; an ophthalmic disease or condition; cancer; oedema; emesis; a dysthymic disorder; and reflex sympathetic dystrophy.
2. The method of claim 1, wherein said disease, disorder or condition is a CNS disorder selected from the group consisting of: psychosis; anxiety; and depression.
3. The method of claim 1, wherein said disease, disorder or condition is addiction withdrawal from alcohol or a narcotic.
4. The method of claim 1, wherein said disease, disorder or condition is neuropathic pain or postherpetic pain.
5. The method of claim 1, wherein said disease, disorder or condition is a neurodegenerative disease selected from the group consisting of: Alzheimer's disease; AIDS-related dementia; Parkinson's disease; amyotrophic lateral sclerosis; Huntington's disease; and Down's syndrome.
6. The method of claim 1, wherein said disease, disorder or condition is an autoimmune disease selected from the group consisting of: systemic lupus erythmatosis; and multiple sclerosis.

7. The method of claim 1, wherein said disease, disorder or condition is of the gastrointestinal tract and is selected from the group consisting of: colitis; Crohn's disease; and irritable bowel syndrome.

8. The method of claim 1, wherein said disease, disorder or condition is a vasospastic disease selected from the group consisting of: migraine headache; Reynaud's disease; and angina.

9. The method of claim 1, wherein said disease, disorder or condition is a skin disorder or condition selected from the group consisting of: sunburn; psoriasis; dermatitis; urticaria; and inflammation.

10. The method of claim 1, wherein said disease, disorder or condition is a collagen-related disorder selected from the group consisting of: fibrositis; scleroderma; and eosinophilic fascioliasis.

11. The method of claim 1, wherein said disease, disorder or condition is hypertension or other cardiovascular disease or condition.

12. The method of claim 1, wherein said disease, disorder or condition is a urinary tract disorder selected from the group consisting of: incontinence; cystitis; bladder hyperreflexia; and bladder hypermotility.

13. The method of claim 1, wherein said disease, disorder or condition is an arthritic disease selected from the group consisting of: rheumatoid arthritis; and osteoarthritis.

14. The method of claim 1, wherein said disease, disorder or condition is an ophthalmic disease or condition selected from the group consisting of: proliferative vitreoretinopathy; ocular injury; and conjunctivitis.

15. The method of claim 1, wherein said disease, disorder or condition is small cell carcinoma of the lung or other cancer.

16. The method of claim 1, wherein said disease, disorder or condition is selected from the group consisting of oedema; emesis; a dysthymic disorder; and reflex sympathetic dystrophy.

5 17. The method of any one of claims 1-16, wherein said peptidase is an exopeptidase selected from the group consisting of: dipeptidyl peptidase IV; quiescent cell proline dipeptidase; dipeptidyl peptidase 8; and attractin.

10 18. The method of claim 17, wherein said exopeptidase is administered at a dose of between 1 µg and 1 mg.

0989433-020301
T0E040"EE425850